ABSTRACT:
Chemotherapy induced nausea and vomiting (CINV) is one of the few mostly observed distressing toxicity of cancer treatment. Aprepitant (neurokinin-1(NK1) receptor antagonist) is used with other medications to prevent nausea and vomiting. The primary objective was to compare the efficacy of aprepitant-based antiemetic regimen and standard antiemetic regimen for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients who received chemotherapy and To evaluate the effect of aprepitant, neurokinin-1(NK1) receptor antagonist with 5-HT3 receptor antagonist and a corticosteroid is to enhance antiemetic protection significantly in patients who receiving chemotherapy. It’s a Prospective randomized case control study was conducted over a period of 6 months in well established cancer institute in kerala. In this study we found that the severity of nausea was less among those in the aprepitant group compared with the control group over a period of one week after chemotherapy (P < 0.05) and the use of rescue antiemetics was lower in the aprepitant group than in the control group during one week after chemotherapy (P < 0.03).Finally we concluded that the Aprepitant (neurokinin-1(NK1) receptor antagonist) was significantly reduce CINV and improve the quality of life, So we conclude that it has an important clinical advance in the supportive care of cancer patients with chemotherapy.